Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30918204 | 0.97 | CTSB (0.48) | PTPN1CTSLCTSBCTSSCTSK | |
| SCHEMBL31089971 | 0.95 | OPRD1 (0.45) | PTPN1OPRD1OPRM1OPRK1 | |
| SCHEMBL30918202 | 0.91 | PTPN1 (0.45) | PTPN1CTSLCTSBCTSSCTSK | |
| SCHEMBL30918284 | 0.91 | PTPN1 (0.45) | PTPN1CTSLCTSBCTSSCTSK | |
| SCHEMBL31028496 | 0.87 | OPRD1 (0.45) | PTPN1OPRD1OPRM1OPRK1 | |
| SCHEMBL31090039 | 0.87 | OPRD1 (0.45) | PTPN1OPRD1OPRM1OPRK1 | |
| SCHEMBL30918231 | 0.85 | KMT2A (0.47) | PTPN1OPRD1 | |
| SCHEMBL29101925 | 0.85 | KMT2A (0.47) | PTPN1OPRD1 | |
| SCHEMBL31089986 | 0.85 | KMT2A (0.47) | PTPN1OPRD1 | |
| SCHEMBL30712765 | 0.85 | KMT2A (0.47) | PTPN1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293569-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATE | PINOTBIO, INC. (KR) | 2024-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293569-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATE | BCR, IGSF11, STT3B | PTPN1 3637/4885CTSL 2222/4885CTSB 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.